

TABLES

TABLE 18: FIVE-YEAR RELATIVE SURVIVAL RATES^a FOR MALIGNANT BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS BY SITE^b AND GENDER, SEER 1973-2002

ICDO CODE	SITE ^{b,c}	MALES		FEMALES		TOTAL	
		N	5-YR	N	5-YR	N	5-YR
C71.1-C71.4	Frontal, temporal, parietal, and occipital lobes of the brain	11,738	22.2	8,707	24.1	20,445	23.0
C71.0	Cerebrum	1,331	19.9	1,036	22.6	2,367	21.1
C71.5	Ventricle	442	49.6	313	51.6	755	50.4
C71.6	Cerebellum	1,439	63.0	1,048	68.6	2,487	65.3
C71.7	Brain stem	887	40.4	786	39.0	1,673	39.7
C71.8-C71.9	Other brain	6,073	17.7	4,642	20.7	10,715	19.0
C72.0-C72.1	Spinal cord and cauda equina	694	72.2	532	70.3	1,226	71.4
C72.2-C72.5	Cranial nerves	175	85.4	164	83.6	339	84.5
C72.8-C72.9	Other nervous system	271	26.3	154	38.8	425	30.7
C70.0-C70.9	Meninges (cerebral and spinal)	308	49.5	344	64.7	652	57.5
C75.1-C75.2	Pituitary	65	77.5	82	81.0	147	79.2
C75.3	Pineal	270	65.6	72	57.5	342	64.0
C30.0 (9522:9523)	Olfactory tumors of the nasal cavity	80	71.9	70	78.7	150	76.1

^aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

^bThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER Site/Histology Validation List.

^cIn contrast to survival estimates reported in previous editions of the CBTRUS statistical report, brain lymphomas are included.

Abbreviation: SEER, Surveillance, Epidemiology, and End Results.

TABLE 19: ONE-, TWO-, THREE-, FOUR-, FIVE-, AND TEN-YEAR RELATIVE SURVIVAL RATES^{a,b} FOR SELECTED MALIGNANT BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS^c, SEER 1973-2002

HISTOLOGY	NO. OF CASES	1-YR	2-YR	3-YR	4-YR	5-YR	10-YR
Pilocytic astrocytoma	1,198	95.7	94.2	93.3	91.9	91.3	89.3
Diffuse astrocytoma	727	73.9	61.8	55.2	50.6	46.9	38.7
Anaplastic astrocytoma	2,294	60.3	44.0	37.1	32.6	29.4	22.2
Astrocytoma, NOS	7,277	59.8	47.3	42.6	39.7	37.1	31.1
Glioblastoma	15,793	29.3	8.7	5.1	3.8	3.3	2.3
Oligodendroglioma	1,868	89.7	83.4	79.0	74.2	70.5	53.9
Anaplastic oligodendroglioma	380	76.4	59.0	53.9	46.5	40.1	30.1
Ependymoma/anaplastic ependymoma	1,225	87.6	81.4	75.4	72.7	70.6	62.5
Mixed glioma	799	84.7	73.3	66.6	60.5	57.1	44.6
Glioma malignant, NOS	2,687	49.7	37.3	34.3	32.2	30.6	27.0
Neuroepithelial	242	60.5	49.1	43.8	41.2	40.3	33.7
Malignant neuronal/gliol, neuronal and mixed	318	83.4	71.6	67.2	63.6	62.5	54.9
Embryonal/primitive/medulloblastoma	1,452	80.6	71.0	64.8	59.4	55.7	47.1
Lymphoma	2,499	36.6	26.8	22.1	19.3	16.9	11.4
TOTAL: ALL BRAIN AND CNS^{c,d}	41,723	51.5	37.3	33.2	30.8	29.1	25.3

^aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

^bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten years, respectively.

^cIn contrast to survival estimates reported in previous editions of the CBTRUS statistical report, brain lymphomas, olfactory tumors of the nasal cavity, and malignant tumors of the pituitary and pineal glands are included.

^dIncludes histologies not listed in this table.

Abbreviations: SEER, Surveillance, Epidemiology, and End Results; NOS, not otherwise specified.